![conference banner](/images/conference-banner.jpeg)
Abstract
Lung cancer kills approximately 1.3 million citizens in the world annually. The tyrosine kinase inhibitors (TKI) erlotinib and gefitinib are effective anti-tumor agents especially in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The goal is to increase the potency of TKI in lung cancer patients with wild type EGFR. G protein-coupled receptors (GPCR) transactivate the wild type EGFR in lung cancer cells. The GPCR can be activated by peptide agonists causing phosphatidylinositol turnover or stimulation of adenylylcyclase. Recently, nonpeptide antagonists were found to inhibit the EGFR transactivation caused by peptides. Nonpeptide antagonists for bombesin (BB), neurotensin (NTS) and cholecystokinin (CCK) inhibit lung cancer growth and increase the cytotoxicity of gefitinib. The results suggest that GPCR transactivation of the EGFR may play an important role in cancer cell proliferation.
Keywords: Epidermal growth factor receptor, G protein-coupled receptor, lung cancer, non-peptide receptor antagonists, peptide receptor agonists, transactivation of tyrosine kinase receptors.
Current Drug Targets
Title:EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer
Volume: 17 Issue: 5
Author(s): Terry W. Moody, Bernardo Nuche-Berenguer, Taichi Nakamura and Robert T. Jensen
Affiliation:
Keywords: Epidermal growth factor receptor, G protein-coupled receptor, lung cancer, non-peptide receptor antagonists, peptide receptor agonists, transactivation of tyrosine kinase receptors.
Abstract: Lung cancer kills approximately 1.3 million citizens in the world annually. The tyrosine kinase inhibitors (TKI) erlotinib and gefitinib are effective anti-tumor agents especially in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The goal is to increase the potency of TKI in lung cancer patients with wild type EGFR. G protein-coupled receptors (GPCR) transactivate the wild type EGFR in lung cancer cells. The GPCR can be activated by peptide agonists causing phosphatidylinositol turnover or stimulation of adenylylcyclase. Recently, nonpeptide antagonists were found to inhibit the EGFR transactivation caused by peptides. Nonpeptide antagonists for bombesin (BB), neurotensin (NTS) and cholecystokinin (CCK) inhibit lung cancer growth and increase the cytotoxicity of gefitinib. The results suggest that GPCR transactivation of the EGFR may play an important role in cancer cell proliferation.
Export Options
About this article
Cite this article as:
Moody W. Terry, Nuche-Berenguer Bernardo, Nakamura Taichi and Jensen T. Robert, EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450116666150107153609
DOI https://dx.doi.org/10.2174/1389450116666150107153609 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Characterization of Linezolid loaded Biocompatible Solidlipid
based Nanocarrier for Enhanced Lung Deposition and Anti-tubercular
Activity: Next Generation tailor-made Carrier for Dry Powder Inhaler
Current Indian Science Molecular Design and Medicinal Applications of Nano-Nitric Oxide Delivery Systems
Current Medicinal Chemistry Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Potential of Microencapsulate Implants: Patents and Clinical Trials
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Effect of Pioglitazone and Cetuximab on Colon Cancer Stem-like Cell (CCSLCs) Properties
Current Stem Cell Research & Therapy Identification of Prognostic Markers and Potential Therapeutic Targets using Gene Expression Profiling and Simulation Studies in Pancreatic Cancer
Current Computer-Aided Drug Design Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond
Current Drug Therapy Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design The Diterpenoids of the Genus Elaeoselinum (Apiaceae) and their Biological Properties
Current Organic Chemistry Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer
Current Pharmaceutical Design Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials